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Abstract
Background Prior studies suggested that obstructive sleep
apnea (OSA) promotes recurrence of arrhythmia in patients
after atrial fibrillation (AF) ablation.
Methods In this prospective, long-term, observational study,
we enrolled 290 consecutive patients admitted for AF
ablation. Prior to the ablation, all patients underwent a
polygraphy sleep study for the diagnosis of OSA. After
the procedure, patients were followed up for mean time of
30 months for AF reoccurrence. OSA was diagnosed when
apnea–hypopnea index (AHI) was ≥5. Patients were subse-
quently divided into groups according to the OSA severity:
mild OSA (AHI 5–15/h), moderate OSA (AHI >15 and ≤30/h),
and severe (AHI >30/h).
Results After excluding patients disqualified from the proce-
dure, and those with central sleep apnea, the study population
consisted of 251 patients, mean age 57.6 years [163 (64.9 %)
male]. OSAwas present in 115 (45.8 %) patients, while in 137
(54.6 %) cases, we observed reoccurrence of AF. Recurrence
was more often in patients with, than without, OSA (65.2 vs.
45.6 %; p=0.003). We also observed that along with rising
OSA severity rose also the number of patients in whom AF
was detected during the follow-up period (45.6 vs. 66.2 vs.
57.6 vs. 81.8 %; p=0.005; for non-OSA, mild, moderate, and
severe, respectively).
Conclusions OSA is highly prevalent in AF patients. The
presence of OSA lowers chances on successful AF ablation.
Early screening, and treatment for OSA in AF patients, may
improve low success rates of AF ablation procedures.
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Introduction
Catheter ablation is a definitive method for restoration of sinus
rhythm in atrial fibrillation (AF) patients. Unfortunately, the
efficacy of the procedure depends on many clinical aspects
and varies greatly between patients. Factors influencing abla-
tion outcome include type of AF, and its duration, patient age,
comorbidities, and echocardiographic parameters, mostly
associated with left atrial diameters [1–5]. Many of these
are associated with alteration in intracardiac hemodynamics,
causing left atrial overload and its structural and electrical
remodeling [6, 7]. One of these is obstructive sleep apnea
(OSA), a sleep disorder affecting many patients with AF.
OSA contributes negatively to natural history of AF, pa-
tients’ risk profile, and prognosis [8–10]. Prior studies have
suggested that OSA promotes recurrence of arrhythmia in
patients after catheter ablation for AF. A majority of those
studies are retrospective or small or include only patients
with symptoms of OSA or at high clinical suspicion of the
disease. The present study aims to prospectively assess the
relationship between OSA and sinus rhythm maintenance in
patients after pulmonary vein isolation, in an unselected
group of continuous AF patients.
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We designed a prospective, observational cohort study. Con-
secutive patients with primary diagnosis of AF qualified for
first-ever catheter ablation between 2011 and 2013 were en-
rolled. During a night prior to procedure, all patients
underwent a whole-night sleep study for diagnosis of sleep-
disordered breathing and were subsequently followed up for a
mean of 30 months for arrhythmia recurrence. Only patients
without previously diagnosed OSAwere included, and inclu-
sion criteria were not based upon any clinical signs or suspi-
cion of underlying sleep-disordered breathing. The study was
designed and implemented in accordance with the Declaration
of Helsinki, and the study protocol was approved by the
University Ethics Committee. Written informed consents for
both ablation procedure and study participation were obtained
from every patient prior to the enrollment. Declining to
sign a consent or its later withdrawal resulted in exclusion
from the study.
Inclusion criteria included age ≥18 and ≤75 years and
qualification for catheter ablation of AF made prior to the
study enrollment, made in accordance with the current guide-
lines described in detail in the documents of both the Europe-
an Society of Cardiology and American Heart Association
[11, 12]. Paroxysmal AF was defined in accordance with the
definitions of the European Society of Cardiology, as self-
terminating, usually within 48 h, which may continue for up to
7 days, and persistent AF was defined when AF episode either
lasted longer than 7 days or required termination by cardio-
version, either with drugs or by direct current cardioversion
[11, 13]. Exclusion criteria were as follows: prior ablation for
AF; previous diagnosis of OSA; presence of contraindications
for polygraphy study including acute and/or chronic pulmo-
nary diseases like obstructive pulmonary disease or active
tuberculosis, neuromuscular disease, hemochromatosis, se-
vere neurologic, or psychiatric disorders; diagnosis of central
sleep apnea made during the study; contraindications for the
ablation procedure including current hyperthyroidism or
hypothyroidism or premature termination of the procedure;
fatal condition with estimated life expectancy of ≤6 months;
or significant cardiac arrhythmia other than AF discovered in
electrophysiology during ablation procedure, which forced the
operators to switch from pulmonary vein isolation to other
types of ablation (i.e., in case of ventricular arrhythmia or
atrial flutter).
Ablation procedure
Radiofrequency catheter ablations were performed by expe-
rienced operators in a high-volume, tertiary university hos-
pital, performing approximately 200 AF ablations per year.
Ablation procedure was described in detail previously [14].
One quadripolar catheter was placed in the coronary sinus
and one in the right ventricle. The left atrium was accessed
through a single or double transseptal puncture (or patent
foramen ovale, if present) and a 10-pole circumferential
15–25-mm Lasso (Biosense Webster, Diamond Bar, CA,
USA) or Optima (St. Jude Medical, Minnetonka, MN, USA),
and 4-mm non-irrigated tip ablation (Marinr, Medtronic,
Minneapolis, MN, USA) or irrigated Navistar ThermoCool
(Biosense Webster, Diamond Bar, CA, USA) catheters were
used for mapping and radiofrequency ablation. After
transseptal puncture, the patients were heparinized throughout
left atrial access (target activated clotting time 300–400 s).
Fluoroscopy and an electroanatomic system (CARTO or
LocaLisa) were used to navigate the catheters. The following
settings were used while delivering radiofrequency energy:
non-irrigated tip ablation—temperature limit of 55 °C and a
power limit of 35 W; irrigated tip ablation—temperature limit
48 °C, power limit 35 and 30 W on posterior wall. All
electrograms were displayed on an electrophysiological re-
cording system. The endpoint of the procedure was the isola-
tion of pulmonary vein potentials (PVP) in all pulmonary
veins. If the patient was on AF, cardioversion was performed
to verify the isolation during sinus rhythm.
Diagnosis of OSA
In every patient, an overnight sleep study was performed
using a portable device for diagnosing the sleep disorders
(Embletta Gold; Flaga, Reykjavik, Iceland), which is a level
3 sleep monitoring tool, according to recommendations of the
European Respiratory Society and the European Society of
Hypertension feasible for objective confirmation of OSA di-
agnosis [15]. The device recorded data from greater than four
channels including respiratory movements or respiratory ef-
fort, airflow, heart rate, ECG, and oxygen saturation. To avoid
bias, obtained data were manually scored by an experienced
physician specialized in sleep medicine, with respect to the
current definitions and recommendations of the American
Academy of Sleep Medicine [16]. Apnea was defined as a
cessation of airflow lasting 10 s, and hypopnea was defined as
a recognizable transient reduction (but not complete cessation)
of breathing for ≥10 s, a decrease of greater than 50 % in the
amplitude of a validated measure of breathing, or a reduction
in amplitude of less than 50 % associated with oxygen
desaturation of 4% or more. Desaturation was defined a blood
oxygen saturation of 90 % or lower. Contrary to other studies
(which focus rather on OSA syndrome), diagnosis of OSA
was made solely when the apnea–hypopnea index (AHI) in
the recorded study was 5/h or more, irrespectively to daytime
OSA symptoms, which allowed objective evaluation of the
disease severity. Patients were subsequently divided into
groups according to the OSA severity: Mild OSAwas defined
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as an AHI between 5 and 15, moderate OSA was an AHI of
>15 and ≤30/h, and AHI >30/h was the criterion for severe
OSA. All patients with diagnosed OSA were managed
according to the current guidelines, and those with an
AHI of >15/h or AHI >5 with symptoms of excessive
daytime sleepiness were offered a continuous positive
airway pressure treatment [16]. Moreover, patients with
body mass index ≥35 kg/m2 were referred to a clinic
specializing in treatment of obesity and bariatric surgery.
Follow-up methods
Primary endpoint of the study was reoccurrence of the AF,
defined as at least one AF episode of at anymoment during the
follow-up period. Screening methods for AF have various
algorithms in different clinical trials. We applied criteria ex-
trapolated from those defined in the Heart Rhythm Society/
European Heart Rhythm Association/European Cardiac Ar-
rhythmia Society consensus statement, which included AF of
at least 30 s’ duration when assessed with ECG monitoring,
including 24-h ECG Holter monitoring, implantable pace-
makers, implantable defibrillators, and subcutaneous ECG
monitoring devices [17]. Time points for ECG Holter screen-
ing were chosen according to the clinical status and decision
of an attending physician, with at least one mandatory ECG
Holter during the first 6 and 12months after the procedure.We
also included an additional screening criterion; if patients
reported symptoms (i.e., heart palpitations or syncope), which
were electrocardiographically documented to be associated
with AF, previously to ablation, we considered recurrence of
patients' self-reported symptoms after the procedure (even
when not ECG-documented) equal to AF recurrence.
Statistical analysis
Continuous data are presented as mean±standard deviation
(SD) and were compared using the Mann–Whitney test or
Student’s t test. Categorical variables were compared using
either the chi-square or Fisher exact tests. A p value of less
than 0.05 was considered statistically significant, whereas the
confidence intervals (CI) were 95 %. The analysis of variance
was used to compare multiple variables. Multivariate logis-
tic regression analysis was performed to identify the inde-
pendent risk factors of AF recurrence. Statistical analyses
were performed using SAS statistical software version 8.02
(SAS Institute, Inc., Cary, NC, USA).
Results
Study population consisted of 290 patients; in 22 cases, sleep
study was not preformed due to technical issues, lack of
patient’s cooperation, or quality of recorded data was insuffi-
cient to perform analysis. Of 268 remaining cases, in 14
patients, AF ablation was not performed. The procedure was
terminated due to complications or electrophysiological study
revealed arrhythmia not suitable for pulmonary vein isolation.
In three cases, sleep study revealed central sleep apnea.
Of the remaining 251 patients, at the age of 57.6±
10.0 years, 163 (64.9 %) were male. Regarding the cardiovas-
cular risk factors, mean body mass index in the population
was 29.6±4.8 kg/m2, and hypertension and dyslipidemia were
highly prevalent (respectively, in 72.9 and 62.9 % of patients).
The baseline characteristics of the study population are given
in Table 1.
Results of the sleep study showed that OSA (AHI ≥5/h)
was present in 114 (45.4 %) patients. Mean AHI was
15.4±12.2, mean lowest registered blood oxygen satu-
ration was 81.8±6.5 %, and total time in desaturation
was 26.8±43.1 min.
OSA patients were older (59.7±7.8 vs. 55.7±11.3 kg,
p=0.01), had higher body mass index (30.8±5.3 vs. 28.5±
4.1 kg/m2, p=0.0002), had higher neck circumference
(41.2±3.8 vs. 39.3±3.3 cm, p=0.0001), and had higher waist
circumference (108.6±12.6 vs. 107.6±88.1 cm, p<0.0001)
than patients without OSA. Paroxysmal form of the arrhyth-
mia was more often noticed in non-OSA patients, while the
Table 1 Baseline characteristics of the study population
Parameter Mean±SD or n (%)




Body mass index (kg/m2) 29.6±4.8
Neck circumference (cm) 40.2±3.6
Waist circumference (cm) 108.1±66.1
SBP (mm Hg) 131.5±16.5
DBP (mm Hg) 80.6±11.1
HR (beats per min) 74.8±15.5
Prior myocardial infarction 20 (8.0 %)
Diabetes mellitus 21 (8.4 %)
Hypertension 183 (72.9 %)
Gout 17 (6.8 %)
Smoking 28 (11.2 %)
Alcohol consumption 23 (9.2 %)
Prior stroke 21 (8.4 %)
Peptic ulcer disease 44 (17.5 %)
Dyslipidemia 158 (62.9 %)
Family history of CVD 100 (39.8 %)
Paroxysmal AF 176 (70.1 %)
SD standard deviation, SBP systolic blood pressure, DBP diastolic blood
pressure,HR heart rate, CVD cardiovascular disease, AF atrial fibrillation
Sleep Breath (2015) 19:849–856 851
OSA group more often had persistent AF (p=0.05); detailed
results are presented in Table 2.
Patients were followed up for a mean time of 30 months.
We observed the AF recurrence in 137 (54.6 %) patients,
while 114 of them remained free from arrhythmia during the
whole follow-up period. Recurrence was more often observed
in the group with OSA (65.2 vs. 45.6 %; p=0.003) than in the
group without this disorder. Except for higher heart rate on
admission (77.3±16.3 vs. 71.8±14.1/min, p=0.005), there
were no statistical differences between the group in sinus
rhythm and patients in whom AF recurrence was observed
(Table 3).
When we divided patients into prespecified groups
according to AHI, we observed that along with rising
severity of OSA rose also the number of patients in
whom AF was detected during the follow-up period
(45.6 vs. 66.2 vs. 57.6 vs. 81.8 %; p for trend=0.005; for
non-OSA and mild, moderate, and severe OSA, respectively).
Only other significant differences between the groups with
different AHI values concerned only polygraphy parameters
(Table 4).
In the multiple logistic regression analysis, OSA was the
strongest, independent risk factor for AF recurrence (odds
ratio [OR] 2.58; 95 % CI 1.52–4.38; p<0.0001); another risk
factor was history of hyperthyroidism (OR 2.21; 95 % CI
1.91–4.10; p=0.01) (Table 5).
Discussion
The relationship between AF and OSA is very complex.Many
studies have been conducted in order to establish how OSA
promotes the arrhythmia, what is the prevalence of OSA inAF
patients, and if treatment strategies should depend on OSA
and AF coexistence [18–20]. OSA is one of the major prob-
lems in AF patients, contributing negatively not only to dis-
ease course but also to increasing the stroke risk [21]. Its
prevalence is shown to be over 40 % [22]. Patients qualified
for AF ablation tend to be different, for example, in terms of
age and comorbidities than the general AF population, but
currently, a lot of bias can be encountered in qualification for
AF [23].We have previously reported that in patients qualified
Table 2 Comparison of patients




SD standard deviation, OSA
obstructive sleep apnea, Lowest
SpO2 lowest registered blood
oxygen saturation, SBP systolic
blood pressure, DBP diastolic
blood pressure, HR heart rate,
MI myocardial infarction, CVD
cardiovascular disease, AF atrial
fibrillation
Values in bold indicate statistical
significance
Parameter; mean±SD or n (%) OSA+ (n=115) OSA– (n=136) p value
AHI (per hour) 15.4±12.2 1.9±1.4 –
Lowest SpO2 (%) 81.8±6.5 86.5±5.0 <0.0001
Time in desaturation (min) 26.8±43.1 12.3±36.2 <0.0001
Percent time in desaturation (%) 5.8±10.0 3.2±9.9 <0.0001
Oxygen desaturation events (per hour) 15.9±13.0 3.1±3.3 <0.0001
Snoring percent time 12.4±19.7 10.6±18.6 0.11
AF recurrence 75 (65.2 %) 62 (45.6 %) 0.003
Male sex; n (%) 80 (69.6 %) 83 (61.0 %) 0.20
Age (years) 59.7±7.8 55.7±11.3 0.01
Height (cm) 172.0±9.9 172.0±10.7 0.97
Weight (kg) 91.1±17.0 84.6±15.3 0.002
Body mass index (kg/m2) 30.8±5.3 28.5±4.1 0.0002
Neck circumference (cm) 41.2±3.8 39.3±3.3 0.0001
Waist circumference (cm) 108.6±12.6 107.6±88.1 <0.0001
SBP (mm Hg) 132.9±16.7 130.3±16.3 0.23
DBP (mm Hg) 82.0±11.5 79.4±10.7 0.06
HR (beats per min) 76.5±17.4 73.3±13.6 0.13
Prior MI 9 (7.8 %) 11 (8.1 %) 0.87
Diabetes mellitus 12 (10.4 %) 9 (6.6 %) 0.39
Hypertension 91 (79.1 %) 92 (67.6 %) 0.06
Gout 11 (9.6 %) 6 (4.4 %) 0.17
Smoking 10 (8.7 %) 18 (13.2 %) 0.35
Alcohol consumption 13 (11.2 %) 10 (7.4 %) 0.39
Prior stroke 13 (11.3 %) 8 (5.9 %) 0.19
Dyslipidemia 74 (64.3 %) 84 (61.8 %) 0.77
Family history of CVD 41 (35.7 %) 59 (43.4 %) 0.39
Paroxysmal AF 73 (63.5 %) 103 (75.7 %) 0.05
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for AF ablation, OSA prevalence is over 45 %, as it is in the
case of this study [19]. In relationship to the general popula-
tion, OSA rates in AF patients are much higher. In the general
population, OSA is estimated to affect 24% ofmen and 9% of
women, at the age of 30 to 60 years [24].
Causes of this often coexistence are associated with sleep
apnea pathophysiology. Intermittent hypoxia and hypercapnia
caused by apnea are associated with sympathetic and
chemoreflex activation, which lead to vasoconstriction and
increase blood pressure [25, 26]. The presence of OSA affects
also arterial stiffness, causes endothelial dysfunction and pro-
motes atherogenesis and left atrial enlargement, and leads to
aberrant conduction and as a consequence AF [27, 28]. OSA
was also shown to affect cardiac electrical stability, increase
transmural pressure gradient, and distort cardiac configuration
[29]. All those mechanisms were shown to promote de novo
occurrence of AF but are responsible in an equal manner for
recurrence of the arrhythmia after invasive treatment.
In AF patients who undergo catheter ablation procedures,
defining procedure success endpoints is challenging and has
been widely discussed by many scientific societies. Experts
agree that measures of outcome should be tailored to fit
studied population. They have to be chosen in accordance
with the class and etiology of AF, comorbidities, risk factors,
and symptoms of the studied population [17, 30]. Defining
strict Holter or ECG monitoring time endpoints is extremely
challenging. Previous studies have shown that short-term
ECGmonitoring may not detect all AF episodes and therefore
give inadequate information about arrhythmia presence. Var-
ious methods including intermittent short-term ECGs or
prolonged monitoring have shown to be more adequate for
AF detection [31, 32]. In patients after cerebrovascular event,
the newest guidelines recommend to consider AF monitoring
lasting even up to 30 days [33]. Therefore, a 24-h monitoring
in patients after catheter ablation cannot be predictive for the
procedure success outcome. In the present study, we decided
to use more extensive criteria to define recurrence of the
arrhythmia. In addition to the standard, recommended ECG
Holter 6 and 12 months after the procedure, we decided to
include in the analysis all additional ECG recordings obtained
Table 3 Comparison of patients
with sinus rhythm and recurrence
of atrial fibrillation in 30 months
following ablation procedure
Desaturation = blood O2
saturation <90 %
SD standard deviation, OSA
obstructive sleep apnea, Lowest
SpO2 lowest registered blood
oxygen saturation, SBP systolic
blood pressure, DBP diastolic
blood pressure, HR heart rate,
MI myocardial infarction, CVD
cardiovascular disease, AF atrial
fibrillation
Values in bold indicate statistical
significance
Parameter; mean±SD or n (%) Sinus rhythm (n=114) Atrial fibrillation recurrence
(n=137)
p value
AHI (per hour) 6.2±7.7 9.7±12.5 0.01
Lowest SpO2 (%) 85.0±5.8 84.1±6.4 0.25
Time in desaturation (min) 13.4±28.4 22.7±47.0 0.11
Percent time in desaturation (%) 3.5±8.7 5.1±11.0 0.16
Oxygen desaturation events (per hour) 6.5±6.9 10.5±13.1 0.03
Snoring percent time (%) 11.8±19.6 11.1±18.7 0.78
OSA 40 (35.1 %) 75 (54.7 %) 0.003
Male sex 72 (63.2 %) 91 (66.4 %) 0.68
Age (years) 57.6±10.5 57.5±9.6 0.55
Height (cm) 171.4±10.2 172.5±10.4 0.42
Weight (kg) 86.1±14.7 88.8±17.6 0.19
Body mass index (kg/m2) 29.3±4.1 29.8±5.4 0.58
Neck circumference (cm) 40.0±3.1 40.3±4.1 0.61
Waist circumference (cm) 111.7±95.3 104.9±13.6 0.53
SBP (mm Hg) 132.3±16.8 130.8±16.4 0.49
DBP (mm Hg) 80.6±10.9 80.6±11.4 0.99
HR (beats per min) 71.8±14.1 77.3±16.3 0.005
Prior MI 9 (7.9 %) 11 (8.0 %) 0.85
Diabetes mellitus 9 (7.9 %) 12 (8.8 %) 0.99
Hypertension 79 (69.3 %) 104 (75.9 %) 0.30
Gout 6 (5.3 %) 11 (8.0 %) 0.54
Smoking 13 (11.4 %) 15 (10.9 %) 0.93
Alcohol consumption 9 (7.9 %) 14 (10.2 %) 0.68
Prior stroke 6 (5.3 %) 15 (10.9 %) 0.16
Dyslipidemia 71 (62.3 %) 87 (63.5 %) 0.95
Family history of CVD 43 (37.7 %) 57 (41.6 %) 0.90
Paroxysmal AF 86 (75.4 %) 90 (65.7 %) 0.12
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during the follow-up period which were scheduled by the
managing clinicians, and what is exceptional in this study
are also patients’ self-reported symptoms. In every day clinical
practice, it is impossible to provide long-term monitoring
devices to every AF patient; furthermore, an instant ECG is
not accessible for every patient who experiences AF symp-
toms at the moment. We believe that if we consider symptom
recurrence as an arrhythmia episode recurrence, we can im-
prove post-procedural AF detection. For the same reasons, we
decided to provide information on total success rate instead of
time-specific information (i.e., 6 or 12 months). The fact that
the arrhythmia was not detected in the time period does not
prove that it was not present.
As for the results of the procedure, the success rate in the
whole study population was relatively low, but we must
remember that endpoint definitions were stricter and follow-
up period was longer than in the previous studies. The major-
ity of the studies performed in the past used risk scales like
Berlin Questionnaire or Epworth Sleepiness Scale for OSA
diagnosis, which are based only on OSA symptoms [34, 18].
In the present study, we base our observations solely on AHI,
irrespectively of symptoms. AHI is independently associated
with the disease severity and therefore corresponds better with
the clinical status.
The study has several limitations; first of all, only a single
night of polygraphy study was performed, which may cause to
Table 4 Differences between the groups according to obstructive sleep apnea (OSA) severity
Parameter; mean±SD or n (%) Mild OSA (n=71) Moderate OSA (n=33) Severe OSA (n=11)
AHI (per hour) 8.6±2.5 20.9±3.7 43.4±15.8
Time in desaturation (min) 20.4±32.4** 22.5±28.6*** 105.8±87.0**, ***
Lowest SpO2 (%) 83.1±5.4** 81.6±5.5*** 65.9±11.4**, ***
Percent time in desaturation (%) 5.1±8.5 4.3±6.7 13.9±20.1
Oxygen desaturation events (per hour) 10.4±5.0*, ** 21.7±5.7*, *** 47.9±26.2**, ***
Snoring percent time 11.1±18.7 13.3±20.5 17.9±23.9
Male sex 52 (73.2 %) 23 (69.7 %) 5 (45.5 %)
Age (years) 59.6±8.5 60.0±7.2 58.6±7.0
Height (cm) 172.0±9.0 173.2±11.6 169.8±11.3
Weight (kg) 89.2±18.1 93.8±15.1 99.4±22.0
Body mass index (kg/m2) 30.1±5.5 31.3±4.6 34.4±6.3
Neck circumference (cm) 41.1±3.9 41.1±3.4 42.0±4.5
Waist circumference (cm) 106.9±13.2 109.4±11.2 116.9±15.8
SBP (mm Hg) 133.2±16.6 132.1±18.3 131.7±15.1
DBP (mm Hg) 82.8±10.7 81.0±12.9 79.6±12.1
HR (beats per min) 75.4±18.7 80.7±16.7 79.6±15.8
Prior MI 6 (8.5 %) 1 (3.0 %) 2 (18.2 %)
Diabetes mellitus 4 (5.6 %) 6 (18.2 %) 2 (18.2 %)
Hypertension 54 (76.1 %) 28 (84.8 %) 9 (81.8 %)
Gout 8 (11.3 %) 1 (3.0 %) 2 (18.2 %)
Smoking 6 (8.5 %) 3 (9.1 %) 1 (9.1 %)
Alcohol consumption 6 (8.5 %) 6 (18.2 %) 1 (9.1 %)
Prior stroke 9 (12.7 %) 3 (9.1 %) 1 (9.1 %)
Peptic ulcer disease 15 (21.1 %) 5 (15.2 %) 2 (18.2 %)
Dyslipidemia 44 (62.0 %) 22 (66.7 %) 8 (72.7 %)
Family history of CVD 23 (32.4 %) 14 (42.4 %) 4 (36.4 %)
SD standard deviation, OSA obstructive sleep apnea, Lowest SpO2 lowest registered blood oxygen saturation, Total desaturation time time of blood
oxygen saturation <90 %, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, MI myocardial infarction, CVD cardiovascular
disease, AF atrial fibrillation
Statistical significance (p<0.05): *significant difference between mild and moderate OSA group; **significant difference between mild and severe OSA
group; ***Significant difference between moderate and severe OSA group
Table 5 Independent risk factor for AF recurrence
Odds ratio 95 % CI p value
Obstructive sleep apnea 2.58 1.52–4.38 <0.0001
History of hyperthyroidism 2.21 1.91–4.10 0.012
CI confidence interval
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overlook some night-to-night variations. Nevertheless, to our
knowledge, our study is the first study with cross-sectional
design, aimed to determine the impact of OSA on sinus
rhythm after AF ablation in a group of unselected patients
screened with polygraphy. We were therefore able to show
a real-life model of the arrhythmia impact because OSA is
still largely underdiagnosed, and patients, especially
asymptomatic, are rarely screened for the disease. Possibly,
early screening, and treatment for OSA in AF patients,
may improve strategies for selection of patients suitable
for AF ablation procedure.
In conclusion, the study showed that OSA is highly
prevalent in patients with AF. The presence of OSA
lowers chances on successful AF ablation. The rate of
arrhythmia recurrence is rising with the AHI score, which
is a manifestation of the disease severity.
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